Skip to content
OpenCapital
Get started

Arbutus Biopharma Corporation ABUS Research and development accruals

Other financials

Income statement

See full
Revenue$179.1M+10,055%
Operating income$168.9M+757%
Net income$169.7M+792%
EPS (diluted)$0.87+769%

Balance sheet

See full
Cash & equivalents$23.7M-36.1%
Total debt$631.0K-46.9%
Total equity$260.2M+229%
Total assets$277.2M+137%

Cash flow

See full
Operating cash flow-$8.1M+39.4%
CapEx--100%
Free cash flow-$4.7M+55.0%

Valuation

See full
Market cap$871.14M+32.6%
Enterprise value$848.07M+36.6%
P/E5.4×—
P/S4.6×-98.0×

Profitability

See full
Operating margin81.7%+42.1pp
Net margin84%+43.4pp
FCF margin-281.5%-119pp

Returns & leverage

See full
Return on equity94.7%+65.1pp
Debt / equity0×0.0×
Current ratio54.3×+48.3×

Where this comes from

Reported directly by Arbutus Biopharma Corporation in its filing.

Tagged under the XBRL concept abus:AccruedResearchAndDevelopment.

The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arbutus Biopharma Corporation's research and development accruals.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arbutus Biopharma Corporation's research and development accruals?
Arbutus Biopharma Corporation (ABUS) reported research and development accruals of $407K in Q1 2026.
How has Arbutus Biopharma Corporation's research and development accruals changed year-over-year?
Arbutus Biopharma Corporation's research and development accruals decreased by 65.3% year-over-year, from $1.17M to $407K.
What is the long-term trend for Arbutus Biopharma Corporation's research and development accruals?
Over 5 years (2020 to 2025), Arbutus Biopharma Corporation's research and development accruals has grown at a -24.3% compound annual growth rate (CAGR), from $1.65M to $412K.